NEXGEL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.22 USD | -0.45% |
|
+0.45% | +4.23% |
| 01/04 | NEXGEL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 01/04 | Transcript : NEXGEL, Inc., Q4 2023 Earnings Call, Apr 01, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 6.17M 515M | Sales 2025 * | 9.32M 778M | Capitalization | 13.83M 1.15B |
|---|---|---|---|---|---|
| Net income 2024 * | -4M -334M | Net income 2025 * | - 0 | EV / Sales 2024 * | 2.24 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.48 x |
| P/E ratio 2024 * |
-3.31
x | P/E ratio 2025 * |
-27.8
x | Employees | 19 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.18% |
More Fundamentals
* Assessed data
More news
Latest transcript on NEXGEL, Inc.
More press releases
| 1 day | -0.45% | ||
| 1 week | +0.45% | ||
| Current month | +4.72% | ||
| 1 month | +3.26% | ||
| 3 months | -1.11% | ||
| 6 months | +16.23% | ||
| Current year | +4.23% |
1 week
2.10
2.26
1 month
1.982.36
Current year
1.983.14
1 year
1.453.14
3 years
1.094.66
5 years
1.094.66
10 years
1.094.66
| Managers | Title | Age | Since |
|---|---|---|---|
Adam Levy
CEO | Chief Executive Officer | 61 | 10/19/10 |
Adam Drapczuk
DFI | Director of Finance/CFO | 48 | 01/21/01 |
Gregory J. Robb
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Scott Henry
BRD | Director/Board Member | 53 | 16/23/16 |
Nachum Stein
BRD | Director/Board Member | 75 | 10/19/10 |
Jerome Zeldis
BRD | Director/Board Member | 74 | 01/20/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 2.22 | -0.45% | 2,803 |
| 02/24/02 | 2.23 | +1.36% | 11,112 |
| 01/24/01 | 2.2 | +3.77% | 1,171 |
| 30/24/30 | 2.12 | +0.95% | 7,028 |
| 29/24/29 | 2.1 | -4.98% | 5,465 |
Delayed Quote Nasdaq, May 04, 2024 at 02:00 am IST
More quotes
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CG labs segment comprises the CG Converting and Packaging, LLC used for the Companyâs converting and packaging business, which is based in Granbury, Texas. All of its gel products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Its hydrogel consumer products are marketed under the brand names MedaGel and LumaGel Beauty.
Sector
Pharmaceuticals
Calendar
09/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.22
USD
Average target price
6
USD
Spread / Average Target
+170.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.23% | 13.83M | |
| +26.08% | 662B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 289B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B |
- Stock Market
- Equities
- NXGL Stock